Search results
Results from the WOW.Com Content Network
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.
On Nov. 8, the U.S. Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound, which, according to clinical trials, helped participants lose up to 52 pounds in 16 months.
The Food and Drug Administration on Wednesday approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that was shown in clinical trials to help people lose up to 52 pounds in 16 months.
The Food and Drug Administration on Wednesday approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that was shown in clinical trials to help people lose up to 52 pounds in 16 months.
The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound.
The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. The approval opens up a wide market of patients for Lilly at a time when ...
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as ...
Zepbound, made by Eli Lilly, is the newest FDA-approved drug for weight loss. (It was previously a diabetes treatment known as Mounjaro.) FDA Approves Zepbound, the Most Potent Weight Loss Drug Yet